Kymriah

Sep 02, 2024

CAR-T cells offer a lasting benefit through a single treatment, sparing patients with high-risk conditions from the toxicity associated with salvage chemotherapy and autologous transplants. These approvals have changed the standard of care for patients who are either resistant to initial treatment or experience ear...

Dec 16, 2022

CAR T-cell therapy is a type of immunotherapy that uses your body's white blood cells to fight your lymphoma. It uses a particular kind of white blood cell known as T lymphocytes or T cells. An essential part of CART therapies is lymphodepleting conditioning, which is administered to the patient before infusion of ...

May 31, 2022

Bristol-Myers Squibb’s Opdivo Gets FDA Approval for Esophageal Cancer The FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced Esophageal Cancer, encroaching on the territory belonging to Merck & Co’s rival Keytruda. The latest...

Apr 02, 2021

Chimeric Antigen Receptor (CAR) Therapies have changed the treatment paradigm of hematological malignancies to a vast extent. These personalized therapies have not only evolved as a game-changer in the field of medicine but also in the lives of the patients. Until the last approvals made by Novartis and Kite Pha...

Apr 10, 2020

DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflic...

Feb 18, 2020

The third edition of CAR-TCR Summit Europe is a one-stop platform that provides attendees with a holistic view of the Gene therapy market, listing the solutions to the plausible hurdles that come across in the process. Hosting over 1000 industry-experts, the CAR TCR Summit is tailored for pharma & biotech play...

Aug 31, 2018

AbbVie Receives USFDA Approval for Imbruvica Plus Rituximab as First Chemotherapy-Free Combination Treatment for Waldenström's Macroglobulinemia Adults AbbVie announced that the USFDA approved Imbruvica (ibrutinib) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (W...